Skip to content
ImmuPharma PLC
  • Science
    • Our Science
    • Autoimmunity
      • P140
      • Type M & Diagnostic
    • Type 1 Diabetes
      • Kapiglucagon
    • Anti-infectives
      • BioAMB
      • BioCIN
    • Pipeline
  • Company
    • Mission
    • About Us
    • Our Team
    • ImmuPharma Biotech
  • Investors
    • Investors
    • AIM Rule 26 Information
    • Regulatory News
    • Corporate Governance
    • Board of Directors
    • Annual Reports
    • Advisers
    • Email Alert
  • Updates
    • Announcements
    • Interviews
    • In the Media
  • Contact

In the Media


  • Charles Archer

    Charles Archer

    Oct 15, 2025

    Immupharma. The Immunormalizer: How a Small British Biotech Might Have Cracked the Autoimmune Code.

  • Breakout Capital

    Breakout Capital

    Oct 4, 2025

    Ultimate Breakouts with Alan Green  4 October 2025 The deep dive with Alan Green,  “Ultimate Breakouts”

  • Analyst Research by Dr Martin Hall

    Analyst Research by Dr Martin Hall

    Mar 7, 2023

    ImmuPharma research notes can be accessed either via:

  • AIM Rule 26
  • Contact information
  • Disclaimer
  • Privacy Policy

© ImmuPharma PLC 2005-2025 | All rights reserved